Institutional Ownership Vaxcyte, Inc. (PCVX)
This table provides information about the institutional ownership of Vaxcyte, Inc. (PCVX). We have compiled data on the 269 institutions that hold shares in the stock, with a total of 97.1 Million shares, which have been reported (via 13F filing form) to have a value of $6.82 Billion.
| Holding | Report Date | shares Held | Holding Value (Reported) | Last Trade | Trade History |
|---|---|---|---|---|---|
|
Vanguard Group Inc
Valley Forge, PA |
May 10, 2024 Q1 2024 |
9,737,254
shares
|
$684 Million
0.01% of portfolio
|
Q1 2024
Added 15.2%
|
|
|
Black Rock Inc.
New York, NY |
May 10, 2024 Q1 2024 |
9,513,007
shares
|
$668 Million
0.02% of portfolio
|
Q1 2024
Added 10.93%
|
|
|
Janus Henderson Group PLC
London, X0 |
May 15, 2024 Q1 2024 |
7,673,868
shares
|
$539 Million
0.29% of portfolio
|
Q1 2024
Added 9.92%
|
|
|
Wellington Management Group LLP
Boston, MA |
May 15, 2024 Q1 2024 |
4,919,370
shares
|
$346 Million
0.06% of portfolio
|
Q1 2024
New holding
|
|
|
Capital Research Global Investors
Los Angeles, CA |
May 14, 2024 Q1 2024 |
4,140,521
shares
|
$291 Million
0.07% of portfolio
|
Q1 2024
Added 20.36%
|
|
|
T. Rowe Price Investment Management, Inc.
Baltimore, MD |
May 15, 2024 Q1 2024 |
3,552,967
shares
|
$250 Million
0.15% of portfolio
|
Q1 2024
Added 185.14%
|
|
|
State Street Corp
Boston, MA |
May 15, 2024 Q1 2024 |
3,337,092
shares
|
$234 Million
0.01% of portfolio
|
Q1 2024
Reduced 1.55%
|
|
|
Price T Rowe Associates Inc
Baltimore, MD |
May 15, 2024 Q1 2024 |
3,176,181
shares
|
$223 Million
0.03% of portfolio
|
Q1 2024
Added 18.61%
|
|
|
Darwin Global Management, Ltd.
St. Helier, Y9 |
May 15, 2024 Q1 2024 |
2,750,804
shares
|
$193 Million
32.04% of portfolio
|
Q1 2024
Added 374.31%
|
|
|
Geode Capital Management, LLC
Boston, MA |
May 13, 2024 Q1 2024 |
2,287,375
shares
|
$161 Million
0.01% of portfolio
|
Q1 2024
Added 15.9%
|
|
|
Franklin Resources Inc
San Mateo, CA |
May 13, 2024 Q1 2024 |
2,147,656
shares
|
$151 Million
0.05% of portfolio
|
Q1 2024
Added 99.43%
|
|
|
Abingworth LLP
London, X0 |
Feb 10, 2023 Q4 2022 |
2,019,057
shares
|
$142 Million
32.11% of portfolio
|
Q4 2022
Reduced 51.57%
|
|
|
Perceptive Advisors LLC
New York, NY |
May 15, 2024 Q1 2024 |
1,932,759
shares
|
$136 Million
2.77% of portfolio
|
Q1 2024
Added 77.56%
|
|
|
Driehaus Capital Management LLC
Chicago, IL |
May 15, 2024 Q1 2024 |
1,867,807
shares
|
$131 Million
1.4% of portfolio
|
Q1 2024
Added 11.55%
|
|
|
Alliancebernstein L.P.
New York, NY |
May 14, 2024 Q1 2024 |
1,780,703
shares
|
$125 Million
0.04% of portfolio
|
Q1 2024
Reduced 7.02%
|
|
|
Westfield Capital Management CO LP
Boston, MA |
May 10, 2024 Q1 2024 |
1,586,095
shares
|
$111 Million
0.58% of portfolio
|
Q1 2024
Added 8.97%
|
|
|
Pictet Asset Management Sa
Geneva 73, V8 |
Aug 10, 2023 Q2 2023 |
1,480,747
shares
|
$104 Million
0.09% of portfolio
|
Q2 2023
Added 120.98%
|
|
|
Fred Alger Management, LLC
New York, NY |
May 15, 2024 Q1 2024 |
1,396,711
shares
|
$98.1 Million
0.48% of portfolio
|
Q1 2024
Reduced 16.37%
|
|
|
Jennison Associates LLC
|
May 02, 2024 Q1 2024 |
1,256,883
shares
|
$88.3 Million
0.06% of portfolio
|
Q1 2024
Reduced 14.85%
|
|
|
Paradigm Biocapital Advisors LP
New York, NY |
May 15, 2024 Q1 2024 |
1,239,995
shares
|
$87.1 Million
3.18% of portfolio
|
Q1 2024
New holding
|
|
|
Invesco Ltd.
Atlanta, GA |
May 14, 2024 Q1 2024 |
1,234,509
shares
|
$86.7 Million
0.02% of portfolio
|
Q1 2024
Added 443.95%
|
|
|
Braidwell LP
Stamford, CT |
May 15, 2024 Q1 2024 |
1,212,703
shares
|
$85.2 Million
2.67% of portfolio
|
Q1 2024
Reduced 5.99%
|
|
|
Jpmorgan Chase & CO
New York, NY |
May 10, 2024 Q1 2024 |
1,161,777
shares
|
$81.6 Million
0.01% of portfolio
|
Q1 2024
Added 186.62%
|
|
|
Frazier Life Sciences Management, L.P.
Menlo Park, CA |
May 15, 2024 Q1 2024 |
1,139,405
shares
|
$80.1 Million
4.09% of portfolio
|
Q1 2024
Reduced 2.15%
|
|
|
Orbimed Advisors LLC
San Diego, CA |
May 15, 2024 Q1 2024 |
1,066,131
shares
|
$74.9 Million
1.64% of portfolio
|
Q1 2024
Reduced 7.54%
|
|